Novel anti-obesity medications(AOMs) are being introduced in the context of rapid growth of obesity globally. In particular, the new generation incretin-based therapy has made a breakthrough for the weight management in patients with obesity, with exceptional weight reduction, comprehensive cardiometabolic benefits, as well as favorable safety profile. However, until now, there is still lack of standardized clinical care with novel AOMs. Given the chronic and recurrent nature of obesity, long-term weight management is especially important. Despite this, we have not established a standard of care for the chronic weight management in obesity. To address this, the steering board invited experts with multidisciplinary expertise in obesity management to update the standard of care in obesity management, incorporating the concept of chronic weight management and extensive clinical experience with AOMs. It is expected that this guideline will provide comprehenisve clinical guidance for weight management and long-term benefits to the patients with obesity.

Obesity; Weight management; Chronic; Anti-obesity medication; Guideline